Fatima Garawi
Columbia University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Fatima Garawi.
American Journal of Drug and Alcohol Abuse | 2006
Efrat Aharonovich; Fatima Garawi; Adam Bisaga; Daniel J. Brooks; Wilfrid N. Raby; Eric J. Rubin; Edward V. Nunes; Frances R. Levin
Cannabis is the most widely used illicit substance in the United States with especially high prevalence of use among those with psychiatric disorders. Few studies have examined the relationship between concurrent cannabis use and treatment outcome among patients receiving treatment for comorbid substance abuse and psychiatric disorders. This study investigated the effects of cannabis use on treatment retention and abstinence from cocaine among cocaine dependent patients with Attention Deficit Hyperactivity Disorder (ADHD). Cocaine dependent patients diagnosed with current ADHD (DSM-IV, N = 92) aged 25 to 51 participated in a randomized clinical trial of methylphenidate for treatment of ADHD and cocaine dependence in an outpatient setting. The majority of patients (69%) used cannabis during treatment. Results suggest that moderate/intermittent cannabis users had greater retention rates compared to abstainers and consistent users (p = .02). This study is the first to examine concurrent cannabis use in cocaine dependent patients diagnosed with ADHD.
American Journal on Addictions | 2008
Evaristo Akerele; Adam Bisaga; Maria A. Sullivan; Fatima Garawi; Sandra D. Comer; Anil A. Thomas; Edward V. Nunes; Herbert D. Kleber
Dextromethorphan (DM) is a low-affinity, non-competitive NMDA receptor antagonist that has shown promise in preclinical and preliminary clinical studies for the reduction of opioid withdrawal symptoms, but when used at higher doses, it is associated with deleterious side effects attributed to its metabolite, dextrorphan. A clinical trial was therefore conducted to test the withdrawal-suppressant effect of a combination of dextromethorphan with quinidine (DM/Q). Quinidine inhibits the metabolism of dextromethorphan, reducing dextrorphan levels. Opioid-dependent patients were admitted to an inpatient unit, stabilized for three days on morphine (25 mg, sc, every six hours), and randomly assigned on day 2 to DM/Q (30 mg/30 mg, twice a day) (n = 22) or matching placebo (n = 9) prior to the discontinuation of morphine on day 4. Withdrawal symptoms, measured with the Modified Himmelsbach Opioid Withdrawal Scale (MHOWS), increased significantly on days 4 and 5 (Z = 3.70, p = .0002), and by day 6, 90% of the sample (28/31) had dropped out of the study. There were no differences between treatment groups on either outcome measure. The combination of dextromethorphan and quinidine appears ineffective as a primary treatment for opioid withdrawal. Future studies should examine dextromethorphan as an adjunct to other anti-withdrawal medications and focus more on the relationship between dextrorphan levels and withdrawal suppression.
American Journal on Addictions | 2014
Wilfrid N. Raby; Eric A. Rubin; Fatima Garawi; Wendy Y. Cheng; Ella Mason; Lisa Sanfilippo; Stephanie Lord; Adam Bisaga; Efrat Aharonovich; Frances R. Levin; David McDowell; Edward V. Nunes
OBJECTIVE This study tested the hypothesis that the antidepressant venlafaxine would be an effective treatment for cocaine abusers with concurrent depressive disorders. METHODS This was a randomized, 12-week, double-blind, placebo-controlled trial of outpatients (N = 130) meeting DSM-IIIR criteria for cocaine dependence and major depression or dysthymia (by SCID interview). Participants were treated with venlafaxine, up to 300 mg/day versus placebo. All patients received weekly individual manual-guided relapse prevention therapy. Weekly outcome measures included Clinical Global Impression Scale (CGI), self-reported cocaine use, urine toxicology and the Hamilton Depression Scale (Ham-D). RESULTS Mood response, defined as a 50% reduction in the Ham-D between randomization and end of study, was 41% (26/64) on venlafaxine, and 33% (22/66) on placebo (p = .39). Measures of depression (Ham-D and CGI) improved more rapidly on venlafaxine than placebo, but these differences disappeared by weeks 6-8. Cocaine outcomes did not differ between treatment groups, and the proportion of patients achieving three or more consecutive weeks of urine-confirmed abstinence was low (venlafaxine: 16%; placebo: 15%). Reduction in cocaine use was associated with mood response. CONCLUSIONS Overall, venlafaxine was not superior to placebo on either mood or cocaine use outcomes. Mood improvement was associated with improvement in cocaine use. However, placebo mood response was only moderate, and the proportion of patients achieving sustained abstinence was low. This suggests that the subgroup of cocaine-dependent patients with depressive disorders is relatively treatment resistant, and that further research is needed to improve outcomes for these patients.
Drug and Alcohol Dependence | 2006
Frances R. Levin; Suzette M. Evans; Daniel J. Brooks; Aparna S. Kalbag; Fatima Garawi; Edward V. Nunes
Alcoholism: Clinical and Experimental Research | 2007
Suzette M. Evans; Frances R. Levin; Daniel J. Brooks; Fatima Garawi
Drug and Alcohol Dependence | 2006
Adam Bisaga; Efrat Aharonovich; Fatima Garawi; Frances R. Levin; Eric J. Rubin; Wilfrid N. Raby; Edward V. Nunes
Drug and Alcohol Dependence | 2007
Maria A. Sullivan; Fatima Garawi; Adam Bisaga; Sandra D. Comer; Kenneth M. Carpenter; Wilfrid N. Raby; Stephen J. Anen; Adam C. Brooks; Huiping Jiang; Evaristo Akerele; Edward V. Nunes
Journal of Substance Abuse Treatment | 2008
Frances R. Levin; Adam Bisaga; Wilfrid N. Raby; Efrat Aharonovich; Eric J. Rubin; John J. Mariani; Daniel J. Brooks; Fatima Garawi; Edward V. Nunes
Drug and Alcohol Dependence | 2005
Adam Bisaga; Efrat Aharonovich; Fatima Garawi; Frances R. Levin; Eric J. Rubin; Wilfrid N. Raby; Suzanne K. Vosburg; Edward V. Nunes
Human Psychopharmacology-clinical and Experimental | 2007
Adam Bisaga; Margarita Padilla; Fatima Garawi; Maria A. Sullivan; Margaret Haney